Geron Corp (GERN)

Geron is a well managed, dedicated, and supurbly staffed company whose integrity is confirmed by their diligence to thoroughness and transparency to the stockholders. They have made exceptional progress in each and every one of their target categories of research, in the process, reporting and meeting obstacles head-on. Contrary to the negative press regarding the FDA's review of Geron's spinal cord injury tests on rats before permitting them to proceed with tests on humans, it is in fact not a delay as such, but rather part of the process to understand and overcome in progress experimental developments of concern.

No other biotech firm doing similar research has achieved anything close to the level of promise that Geron has achieved, yet the stock of some of those other biotech companies is priced in the $60's.

At the present price of $6.50 or so per share, Geron stock is the best buy out there. I strongly believe Geron is on the verge of several major advances and in the area of human spinal cord injury stem cell repair, a major break-through will be achieved by June of 2010. Until investors see the light, Geron will underpereform.